Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A’s: Abundance, Activation and Antigen-Delivery
Open Access
Abstract
Recent advances in cancer immunotherapy have mainly focused on re-activating T-cell responses against cancer cells. However, both priming and activation of effector T-cell responses against cancer-specific antigens require cross-talk with dendritic cells (DCs), which are responsible for the capturing, processing and presentation of tumour-(neo)antigens to T cells. DCs consequently constitute an essential target in efforts to generate therapeutic immunity against cancer. This review will discuss recent research that is unlocking the cancer-fighting potential of tumour-infiltrating DCs. First, the complexity of DCs in the tumour microenvironment regarding the different subsets and the difficulty of translating mouse data into equivalent human data will be briefly touched upon. Mainly, possible solutions to problems currently faced in DC-based cancer treatments will be discussed, including their infiltration into tumours, activation strategies, and antigen delivery methods. In this way, we hope to put together a broad picture of potential synergistic therapies that could be implemented to harness the full capacity of tumour-infiltrating DCs to stimulate anti-tumour immune responses in patients.Keywords
This publication has 108 references indexed in Scilit:
- IRF4 Transcription Factor-Dependent CD11b+ Dendritic Cells in Human and Mouse Control Mucosal IL-17 Cytokine ResponsesImmunity, 2013
- Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic CellsImmunity, 2012
- Characterization of resident and migratory dendritic cells in human lymph nodesJournal of Experimental Medicine, 2012
- Ovarian cancer progression is controlled by phenotypic changes in dendritic cellsJournal of Experimental Medicine, 2012
- IRF8Mutations and Human Dendritic-Cell ImmunodeficiencyNew England Journal of Medicine, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- The role of CD40 and CD154/CD40L in dendritic cellsSeminars in Immunology, 2009
- Immunogenic and tolerogenic cell deathNature Reviews Immunology, 2009
- Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humansJournal of Experimental Medicine, 2008
- The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissuesNature Immunology, 2008